Table 3.
Ongoing clinical trials on SDT in Glioblastoma
| Title | Identifier | Status | Interventions | Aim | Locations |
|---|---|---|---|---|---|
| Sonodyamic therapy with exablate system in glioblastoma patients (sonic ALA) | NCT04845919 | not yet recruiting | 5-Aminolevulinic acid [5-ALA] | To evaluate the safety and feasibility of SDT with 5-aminolevulinic acid in patients with newly diagnosed cerebral GB using the ExAblate Model 4000 Type-2 “Neuro-System” | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano |
| Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Recurrent GB | NCT05370508 | Recruiting | SONALA-001 (ALA) and exablate device | To evaluate the safety, dose-limiting toxicities, recommended Phase 2 schedule, and preliminary efficacy of SDT using SONALA-001 and Exablate Type-2 device in subjects with recurrent or progressive GB | Ivy Brain Tumor Center, Arizona and MD Anderson Cancer Center,Houston |
| Study to Evaluate 5-ALA Combined with CV01 Delivery of Ultrasound in Recurrent High-Grade Glioma (HGG) | NCT05362409 | Recruiting | 5-Aminolevulinic acid [5-ALA] | To evaluate the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined with CV01 Delivery of Ultrasound for SDT in Patients With recurrent HGG | Northwell. United States, New York |
| Study of Sonodynamic Therapy in participants with recurrent high-grade glioma (HGG) | NCT04559685 | Recruiting | SONALA-001 (ALA) | To evaluate the ascending energy doses of SDT utilizing the Magnetic Resonance focused Ultrasound (MRgFUS) combined with intravenous 5-ALA and efficacy in patients with recurrent HGG | St. Joseph's Hospital and Medical Center |